Skip to content

Heterobivalent fibroblast activation protein-targeted Radiotheranostic ligands integrating cyclic peptide and small-molecule motifs for enhanced tumor retention.

Sep 2026 · Bioorganic chemistry (Print) · Vol 182, pp. 110486 · 0 citations · 42 references
Medicine

Abstract

Fibroblast activation protein (FAP), which is highly expressed in cancer-associated fibroblasts, has emerged as an attractive target for tumor imaging and radionuclide therapy. However, FAP-targeted radioligands suffer from rapid tumor washout, limiting effective dose delivery. The heterobivalent design strategy effectively enhances target engagement and tumor retention, addressing a key limitation of current FAP-targeted radioligands. In this study, six heterobivalent FAP-targeted radioligands (1-6) were rationally designed by incorporating small-molecule FAP inhibitor motifs, including 2-cyanopyrrolidine and 2-pyrrolidinylboronic acid derivatives, into the cyclic peptide scaffold via systematic optimization of the linker structures and conjugation sites. All ligands were successfully radiolabeled with gallium-68, achieving radiochemical purities exceeding 95% and exhibiting favorable hydrophilicity and high in vitro stability. The heterobivalent ligands demonstrated significantly enhanced FAP binding affinity compared with monomeric ligand FAP-2286. The ligands also exhibited increased cellular uptake, pronounced internalization, and reduced efflux in U87MG cells, relative to their monovalent counterparts. In vivo PET/CT imaging in U87MG xenograft-bearing mice revealed rapid clearance from nontarget tissues and substantial tumor accumulation for all tracers, with [68Ga]Ga-5 exhibiting the highest tumor uptake and superior tumor-to-background contrast. Notably, the therapeutic analog [177Lu]Lu-5 displayed the most favorable tumor-to-kidney area under the curve ratio and achieved significantly improved tumor growth inhibition compared with [177Lu]Lu-FAP-2286. Overall, ligand 5 shows promise as an FAP-targeted radiotheranostic agent and demonstrates potential for further translational development.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.